Abstract
In vivo proton magnetic resonance spectroscopy (1H-MRS) has been demonstrated to be successful in the differentiation of benign and malignant breast lesions in a non-invasive manner by detecting increased levels of composite choline (Cho) compounds. Currently there is molecular evidence of increased Cho metabolism in breast cancer cells. In breast malignancies, 1H-MRS achieved a high-overall sensitivity (82%). Most test cases were infiltrating duct carcinoma, but infiltrating lobular, medullary, mucinous and adenoid cystic carcinomas were also positive by 1H-MRS. Large lesional size is a pre-requisite for 1H-MRS testing, and technical problems account for some of the false negative results. Another potential of 1H-MRS is to assess patients’ response to neoadjuvant chemotherapy. In ductal carcinoma in situ, the results of 1H-MRS on the limited number of cases were negative. Most of the assessed benign breast lesions including fibroadenoma, fibrocystic changes, cysts and galactoceles, papilloma, tubular adenoma and phyllodes tumours and were mostly negative by 1H-MRS, with an overall false positive rate was about 8%. Normal breast tissue was almost always negative by 1H-MRS, whereas, lactating breast tissue showed positivity with a slightly different spectrum on further analysis. With the clinical use of stronger field MR scanners and better coils, the sensitivity of 1H-MRS may be further improved. With these improvements, 1H-MRS may potentially be useful in detection of smaller malignant lesions, characterization of malignant lesions into non-invasive or invasive, and as an invaluable tool in disease progression monitoring.
Similar content being viewed by others
References
Orel SG, Schnall MD (2001) MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. Radiology 220:13–30
Stavros AT, Thickman D, Rapp CL, et al. (1995) Solid breast nodules: use of sonography to distinguish between benign and malignant lesions. Radiology 196:123–134
Buchberger W, Niehoff A, Obrist P, et al. (2000) Clinically and mammographically occult breast lesions: detection and classification with high-resolution sonography. Semin Ultrasound CT MR 21:325–336
Degani H, Gusis V, Weinstein D, et al. (1997) Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 3:780–782
Esserman L, Hylton N, Yassa L, et al. (1999) Utility of magnetic resonance imaging in the management of breast cancer: evidence for improved preoperative staging. J Clin Oncol 17:110–119
Warner E, Plewes DB, Shumak RS, et al. (2001) Comparison of breast magnetic resonance imaging, mammography, and ultrasound for surveillance of women at high risk for hereditary breast cancer. J Clin Oncol 19:3524–3531
Madan AK, Nguyen MT, Wakabayashi MN, et al. (2001) Magnification views of mammography decrease biopsy rates. Am Surg 67:687–689
Milz P, Lienemann A, Kessler M, et al. (2001) Evaluation of breast lesions by power Doppler sonography. Eur Radiol 11:547–554
Yeung DK, Cheung HS, Tse GM (2001) Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy—initial results. Radiology 220:40–46
Yeung DK, Yang WT, Tse GM (2002) Breast cancer: in vivo proton MR spectroscopy in the characterization of histopathologic subtypes and preliminary observations in axillary node metastases. Radiology 225:190–197
Cecil KM, Schnall MD, Siegelman ES, et al. (2001) The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 68:45–54
Jacobs MA, Barker PB, Bottomley PA, et al. (2004) Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 19:68–75
Roebuck JR, Cecil KM, Schnall MD, et al. (1998) Human breast lesions: characterization with proton MR spectroscopy. Radiology 209:269–275
Kvistad KA, Bakken IJ, Gribbestad IS, et al. (1999) Characterization of neoplastic and normal human breast tissues with in vivo [1]H MR spectroscopy. J Magn Reson Imaging 10:159–164
Gribbestad IS, Petersen SB, Fjosne HE, et al. (1994) 1H NMR spectroscopic characterization of perchloric acid extracts from breast carcinomas and non-involved breast tissue. NMR Biomed 7:181–194
Tse GM, Cheung HS, Pang LM, et al. (2003) Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 181:1267–1272
Stanwell P, Gluch L, Clark D, et al. (2005) Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol 15:1037–1043
Kim JK, Park SH, Lee HM, et al. (2003) In vivo 1H-MRS evaluation of malignant and benign breast diseases. Breast 12:179–182
Zeisel SH, Da Costa KA, Franklin PD, et al. (1991) Choline, an essential nutrient for humans. FASEB J 5:2093–2098
Zeisel SH (1990) Choline deficiency. J Nutr Biochem 1:332–349
Zeisel SH (1994) Choline modern nutrition in health and disease. 8th edn. Lea & Febiger, Philadelphia, PA
Ting YL, Sherr D, Degani H (1996) Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 16:1381–1388
Katz-Brull R, Margalit R, Bendel P, et al. (1998) Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. MAGMA 6:44–52
Glunde K, Jie C, Bhujwalla ZM (2004) Molecular causes of the aberrant choline phospholipid metabolism in breast cancer. Cancer Res 64:4270–4276
Lean C, Doran S, Somorjai RL, et al. (2004) Determination of grade and receptor status from the primary breast lesion by magnetic resonance spectroscopy. Technol Cancer Res Treat 3:551–556
Cotran RS, Kumar V, Collins T, et al. (eds) (1999) Robbins pathologic bases of disease. 6th edn. Saunders, Philadelphia, PA, pp. 280–282
Aboagye EO, Bhujwalla ZM (1999) Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 59:80–84
Jagannathan NR, Kumar M, Seenu V, et al. (2001) Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 84:1016–1022
Mackinnon WB, Barry PA, Malycha PL, et al. (1997) Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 204:661–666
Tan PH, Aw MY, Yip G, et al. (2005) Cytokeratins in papillary lesions of the breast: is there a role in distinguishing intraductal papilloma from papillary ductal carcinoma in situ? Am J Surg Pathol 29:625–632
Tse GM, Tan PH, Ma TK, et al. (2005) CD44s is useful in the differentiation of benign and malignant papillary lesions of the breast. J Clin Pathol 58:1185–1188
Tse GM, Tan PH (2005) Recent advances in the pathology of fibroepithelial tumours of the breast. Curr Diagn Pathol 11:426–434
Bolan PJ, Nelson MT, Yee D, et al. (2005) Imaging in breast cancer: magnetic resonance spectroscopy. Breast Cancer Res 7:149–152
Guo Y, Cai YQ, Cai ZL, et al. (2002) Differentiation of clinically benign and malignant breast lesions using diffusion-weighted imaging. J Magn Reson Imaging 16:172–178
Hayes C, Padhani AR, Leach MO (2002) Assessing changes in tumour vascular function using dynamic contrast-enhanced magnetic resonance imaging. NMR Biomed 15:154–163
Huang W, Fisher PR, Dulaimy K, et al. (2004) Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 232:585–591
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tse, G.M., Yeung, D.K.Y., King, A.D. et al. In vivo proton magnetic resonance spectroscopy of breast lesions: an update. Breast Cancer Res Treat 104, 249–255 (2007). https://doi.org/10.1007/s10549-006-9412-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-006-9412-8